We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.
Building a leading microbiome company in oncology
We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.
Corporate profile
Press Releases

May 26, 2023: MaaT Pharma Announces Combined General Meeting on June 19, 2023 and the Availability of the Preparatory Documents

May 3, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Media Coverage

April 28, 2023: Microbiome Times – FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013

April 28, 2023: Microbiome Post – MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

April 25, 2023: BioPharma Reporter – FDA lifts 18-month clinical hold on MaaT Pharma’s microbiome therapeutic

April 24, 2023 : Endpoints News – FDA lifts nearly two-year hold on MaaT Pharma’s microbiome therapy, opens door to PhIII
Posters

Restoration of gut microbiota diversity with oral pooled fecal microbiotherapy in acute myeloid leukemia patients after intensive chemotherapy: the phase 1b CIMON trial

Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program

Pooling of faecal material results in standardized and high-richness microbiotherapy products MaaT013 and MaaT033
